Viridian Therapeutics (1S1) AI Stock Analysis

2 Followers

Viridian Therapeutics

(Frankfurt:1S1)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Early Lumvoa commercial adoptionThe initial Lumvoa launch provides evidence that Viridian has moved beyond development toward commercial revenue generation. Patient starts and demand-driven sales create a foundation for broader adoption, future revenue growth, and operating leverage as launch infrastructure matures.

Negative Factors

Heavy cash burnPersistent and worsening cash outflows show that Viridian's current operations are not self-funding. Continued investment in commercialization and development will consume substantial resources, making progress toward profitability and disciplined capital allocation important over the next several quarters.

Viridian Therapeutics (1S1) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 3.55B
Dividend Yield: ―
Average Volume (3M): 130
Price to Earnings (P/E): -8.1
Beta (1Y): -0.05
Revenue Growth: -62.27%
EPS Growth: -11.52%
Country: Germany
Employees: 252
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Viridian Therapeutics Business Overview & Revenue Model

Company Description

Viridian Therapeutics, Inc. is a biotechnology firm committed to creating therapies for patients afflicted by serious illnesses. Its primary development efforts include VRDN-001, a humanized monoclonal anti-IGF-1R antibody currently advancing through...

Viridian Therapeutics Earnings Call Summary

Earnings Call Date:Nov 04, 2026(Q3-2026)|% Change Since:18.75%|Next Earnings Date:Mar 11, 2027

Earnings Call SentimentPositive

The call was strongly optimistic, led by a better-than-expected first quarter for Lumvoa with $24.7 million of revenue, more than 100 treated patients, strong commercial execution, early payer progress, and a well-funded pipeline. Management also emphasized that the launch is still early, broad payer coverage is still developing, and the sustainability of demand and growth must be demonstrated in subsequent quarters.

Positive Updates

Strong Initial Lumvoa Launch

Lumvoa generated $24.7 million in net product revenue during its first quarter on the market, and more than 100 patients had started therapy and completed at least one infusion by September 30. Management said the launch exceeded expectations and that the revenue was driven by patient demand rather than inventory stocking.

Negative Updates

Launch Remains at an Early Stage

Management repeatedly emphasized that it is still only one quarter into the launch and that the strength, sustainability, and rate of growth will need to be evaluated over subsequent quarters. The company did not provide Q4 revenue or patient-add guidance.

Company Guidance

Viridian said it is on track to submit the BLA for elegrobart in the first quarter of 2027, with potential at-home self-administration as infrequently as every eight weeks, and expects to initiate a phase I clinical trial of VRDN-292 in Graves' patients later this quarter; it also expects to share first-in-human results for VRDN-008 later this quarter. The company said enrollment form to infusion typically takes 60-90 days, is on track to achieve broad coverage for Lumvoa six to nine months from launch, and had reached 30% covered lives with a policy in place by the end of the third quarter. It is stopping short of giving any guidance for Q4, but would anticipate some growth going into the next quarter and a good fourth quarter, while CMS’s permanent J-code for Lumvoa will become effective on January 1st, 2027.

Viridian Therapeutics Risk Analysis

Viridian Therapeutics disclosed 74 risk factors in its most recent earnings report. Viridian Therapeutics reported the most risks in the "Tech & Innovation" category.

Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

3 New Risks

1.We may not have the ability to raise the funds necessary to repurchase the 2032 Notes as required upon a fundamental change or event of default, and our future debt may contain limitations on our ability to repurchase the 2032 Notes.Q2, 2026

2.Servicing our 1.75% convertible senior notes due 2032 (the "2032 Notes") requires a significant amount of cash, and we may not have sufficient cash flow to pay our debt.Q2, 2026

3.We remain subject to ongoing regulatory oversight.Q2, 2026

Viridian Therapeutics Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:1S1 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CLDX	61Neutral	$2.41B	-7.00	-52.67%	―	-93.92%	-27.48%
VERA	53Neutral	$2.17B	-5.17	-90.03%	―	―	-48.21%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ZBIO	51Neutral	$1.94B	-2.85	-208.91%	―	-26.67%	-121.60%
MLTX	49Neutral	$1.07B	-3.67	-79.95%	―	―	-10.20%
RARE	48Neutral	$1.65B	-3.22	213.22%	―	15.76%	12.63%

* Healthcare Sector Average

Performance Comparison

DE:1S1 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:1S1	Viridian Therapeutics, Inc.	26.60	1.93	7.82%
CLDX	Celldex Therapeutics	30.15	6.43	27.11%
RARE	Ultragenyx Pharmaceutical, Inc.	16.70	-16.20	-49.24%
MLTX	Moonlake Immunotherapeutics	13.51	0.95	7.56%
VERA	Vera Therapeutics, Inc.	30.48	2.11	7.44%
ZBIO	Zenas BioPharma, Inc.	28.70	-6.96	-19.52%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Viridian Therapeutics AI Stock Analysis